Chemomab Therapeutics Ltd. CMMB
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 1.10M | 881.00K | 975.00K | 994.00K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 2.24M | 1.97M | 2.26M | 3.49M | |
| Operating Income | -2.24M | -1.97M | -2.26M | -3.49M | |
| Income Before Tax | -2.17M | -1.87M | -2.06M | -3.32M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -2.17M | -1.87M | -2.06M | -3.32M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -2.17M | -1.87M | -2.06M | -3.32M | |
| EBIT | -2.24M | -1.97M | -2.26M | -3.49M | |
| EBITDA | -2.23M | -1.96M | -2.25M | -3.47M | |
| EPS Basic | -21.64 | -19.16 | -28.40 | -46.62 | |
| Normalized Basic EPS | -0.17 | -0.15 | -- | -- | |
| EPS Diluted | -21.64 | -19.16 | -28.40 | -46.62 | |
| Normalized Diluted EPS | -0.17 | -0.15 | -- | -- | |
| Average Basic Shares Outstanding | 8.00M | 7.82M | 5.79M | 5.70M | |
| Average Diluted Shares Outstanding | 100.00K | 97.70K | 72.40K | 71.20K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |